SynAct Pharma Valuation Multiples

SynAct Pharma Overview

About SynAct Pharma

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

Founded

2012

HQ

Employees

6

Website

synactpharma.se

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($7M)

EV

$99M

Valuation Multiples

Multiples.vc

Start free trial

SynAct Pharma Financials

SynAct Pharma reported last 12-month revenue of — and negative EBITDA of ($7M).

In the same LTM period, SynAct Pharma generated — in gross profit, ($7M) in EBITDA losses, and had net loss of ($7M).

SynAct Pharma P&L

In the most recent fiscal year, SynAct Pharma reported revenue of — and EBITDA of ($13M).

SynAct Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

SynAct Pharma Stock Performance

SynAct Pharma has current market cap of $104M, and enterprise value of $99M.

SynAct Pharma's stock price is $1.86.

SynAct Pharma Valuation Multiples

SynAct Pharma trades at (13.4x) EV/EBITDA.

SynAct Pharma Financial Valuation Multiples

As of April 18, 2026, SynAct Pharma has market cap of $104M and EV of $99M.

Equity research analysts estimate SynAct Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

SynAct Pharma has a P/E ratio of (15.3x).

SynAct Pharma Margins & Growth Rates

SynAct Pharma's revenue in the last fiscal year grew by —.

SynAct Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.

SynAct Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

SynAct Pharma M&A Activity

SynAct Pharma acquired XXX companies to date.

Last acquisition by SynAct Pharma was on XXXXXXXX, XXXXX. SynAct Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

SynAct Pharma Investment Activity

SynAct Pharma invested in XXX companies to date.

SynAct Pharma made its latest investment on XXXXXXXX, XXXXX. SynAct Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).